Summary
None of the provided claims about MDS/AML treatment are supported by the supplied ONUREG label excerpts as written, and nearly all claims about mechanisms (DNA methyltransferases/histone marks), GVHD treatment/use, corticosteroids/calcineurin inhibitors, and specific GVHD case/improved outcomes are not supported by the provided label information.
Category Scores
Accurate Statements
The supplied label excerpt includes a warning that ONUREG must not be substituted for intravenous or subcutaneous azacitidine because the indications and dosing regimen differ.
Dosage and Administration (2.1) and Risks of Substitution with Other Azacitidine Products (5.1).
Unsupported Statements
Azacitidine (Vidaza) is used to treat myelodysplastic syndromes (MDS).
The provided ONUREG label excerpt for Indications (1) describes acute myeloid leukemia continued treatment, not MDS use; no MDS indication support was provided in the excerpts.
Azacitidine (Vidaza) is used to treat acute myeloid leukemia (AML).
The provided label excerpt for ONUREG (not Vidaza) states indication for continued treatment of adult patients with acute myeloid leukemia under specific remission and inability-to-complete-intensive-therapy criteria; the claim is overly general and does not match the label wording.
Azacitidine inhibits DNA methyltransferases.
No mechanism-of-action statements regarding DNA methyltransferases were provided in the supplied excerpts.
Azacitidine inhibits enzymes responsible for adding methyl groups to DNA.
No such mechanism statements were provided in the supplied excerpts.
Azacitidine can restore the expression of genes normally silenced by DNA methylation.
No gene-expression restoration claims were provided in the supplied excerpts.
Azacitidine treatment reverses aberrant histone marks in patients with graft-versus-host disease (GVHD).
GVHD use and histone-mark reversal are not supported by the supplied ONUREG label excerpts.
Reversal of aberrant histone marks in GVHD patients treated with azacitidine is associated with improved clinical outcomes.
No GVHD-related efficacy/mechanism-outcome statements were provided in the supplied excerpts.
Azacitidine-associated improved clinical outcomes in GVHD include reduced severity of GVHD symptoms.
No GVHD efficacy outcomes were provided in the supplied excerpts.
Azacitidine-associated improved clinical outcomes in GVHD include improved overall survival.
No GVHD efficacy outcomes were provided in the supplied excerpts.
The exact mechanisms by which azacitidine affects histone marks in GVHD are not fully understood.
No histone-mark mechanism statements (or GVHD mechanism discussion) were provided in the supplied excerpts.
Azacitidine inhibits DNA methyltransferases leading to demethylation of DNA.
No mechanism-of-action or demethylation statements were provided in the supplied excerpts.
Demethylation of DNA allows for reactivation of genes that are normally silenced by DNA methylation.
No mechanism-of-action or gene reactivation statements were provided in the supplied excerpts.
Reactivation of genes due to azacitidine-mediated DNA demethylation can contribute to normalization of histone marks.
No mechanism-of-action statements connecting DNA demethylation to histone-mark normalization were provided in the supplied excerpts.
Normalization of histone marks can contribute to resolution of GVHD symptoms.
No GVHD efficacy/mechanistic resolution statements were provided in the supplied excerpts.
Azacitidine may be useful as a treatment for GVHD, particularly in patients with abnormal histone marks.
No GVHD indication or patient-selection guidance was provided in the supplied ONUREG excerpts.
Further research is needed to determine the optimal dosing and administration schedule of azacitidine for GVHD.
No GVHD dosing/administration discussion was provided in the supplied excerpts.
Corticosteroids and calcineurin inhibitors are commonly used to manage GVHD symptoms.
No GVHD treatment-concomitant statements were provided in the supplied excerpts.
Corticosteroids and calcineurin inhibitors can have significant side effects.
No GVHD concomitant drug safety statements were provided in the supplied excerpts.
Corticosteroids and calcineurin inhibitors may not be effective in all patients with GVHD.
No GVHD treatment effectiveness statements were provided in the supplied excerpts.
Azacitidine is described as targeting abnormal histone marks and being a promising alternative to traditional GVHD treatments.
No description of azacitidine targeting histone marks for GVHD or 'promising alternative' language was provided in the supplied excerpts.
In a reported case, a patient with GVHD treated with azacitidine had GVHD symptoms that began to resolve within weeks.
No case report or GVHD case timeline was provided in the supplied excerpts.
In the reported case, the patient was able to discontinue corticosteroids after symptoms began to resolve with azacitidine.
No case report content was provided in the supplied excerpts.
The potential side effects of azacitidine are similar to those of other medications used to treat GVHD.
No GVHD concomitant medication comparison was provided in the supplied excerpts.
Potential side effects of azacitidine include nausea.
No adverse-reaction list for azacitidine/ONUREG was provided in the supplied excerpts.
Potential side effects of azacitidine include vomiting.
No adverse-reaction list for azacitidine/ONUREG was provided in the supplied excerpts.
Potential side effects of azacitidine include fatigue.
No adverse-reaction list for azacitidine/ONUREG was provided in the supplied excerpts.
Contradictions
Low
AI Statement
Azacitidine (Vidaza) is used to treat myelodysplastic syndromes (MDS).
Label Reference
Warnings and Precautions (5.3): 'The safety and effectiveness of ONUREG for treatment of myelodysplastic syndromes have not been established. Treatment of patients with myelodysplastic syndromes with ONUREG is not recommended outside of controlled trials.'
Important Omissions
No claim in the provided list addresses ONUREG-specific approved indication details (AML population defined by achieved CR/CRi and inability to complete intensive curative therapy), which is material for on-label accuracy.
Importance:
Moderate
No claims include ONUREG-specific administration/dosing details (e.g., 300 mg orally once daily Days 1-14 of a 28-day cycle) and key administration cautions (e.g., do not substitute for IV/SC azacitidine, antiemetic prophylaxis, ANC monitoring and not administering with ANC <0.5 Gi/L), which are material for safe/accurate use statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many claims are not supported by the supplied ONUREG label excerpts, especially those asserting GVHD treatment usefulness and mechanistic outcomes; such unsupported on-label/off-label assertions could mislead about indications. The MDS indication claim conflicts with the provided ONUREG safety/efficacy statement discouraging use outside controlled trials.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major mismatch with supplied ONUREG label excerpts: GVHD-related claims and mechanism assertions are unsupported, and the MDS statement conflicts with ONUREG’s provided MDS safety/efficacy warning. AML statement is overly general vs the specific labeled population criteria.
Suggested Improvement
Limit claims to the supplied ONUREG label excerpts (AML continued treatment eligibility, do-not-substitute warning, and ONUREG dosing/monitoring statements when relevant). Remove unsupported GVHD/histone/DNA methylation mechanism and efficacy assertions unless the corresponding label sections are provided.